The present invention relates to a Fab fragment based switchable antibody system for generating site-specific antibody conjugates. Methods are described for the attachment of molecules to specific sites the Fab fragment and for the attachment of the Fab fragment to a target molecule (e.g., an antibody) directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.) The attachment is via binding of the Fab fragment to an epitope linked to the target molecule.

The present invention relates to a Fab fragment based switchable antibody system for generating site-specific antibody conjugates. Methods are described for the attachment of molecules to specific sites the Fab fragment and for the attachment of the Fab fragment to a target molecule (e.g., an antibody) directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.) The attachment is via binding of the Fab fragment to an epitope linked to the target molecule.

In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.

The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.

Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.

Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.

The invention provides methods and compositions for treating allergies that use antibodies or other products of the immune system from whom have already experienced and responded to an allergen. In particular, people who have suffered from an allergic reaction to an allergen but subsequently become desensitized to the allergen produce immune products that may be isolated or reproduced for use in a therapeutic composition.

The present invention relates to a composition comprising at least one polypeptide, which polypeptide comprises the amino acid sequence set out in any one of SEQ ID NOs: 1 to 51 or 101 to 111 or an amino acid sequence having at least about 80% sequence identify thereto and which polypeptide is capable of binding to a fungus. The invention further relates to a composition comprising at least one polypeptide, which polypeptide comprises a CDR1 region having the amino acid sequence set out in any one of SEQ ID NOs: 52 to 67 or 112 to 122, a CDR2 region having the amino acid sequence set out in any one of SEQ ID NOs: 68 to 83 or 123 to 133, and a CDR3 region having the amino acid sequence set out in any one of SEQ ID NOs: 84 to 100 or 134 to 144 and which polypeptide is capable of binding to a fungus. The compositions may be used as anti-fungal compositions.